Epidemiology of Acute Respiratory Distress Syndrome in Chinese ICUs

Overview

The acute respiratory distress syndrome(ARDS)has a high morbidity and mortality in patients admitted to intensive care units(ICUs). It represents a significant public health issue. No large nationwide, multicenters study of ARDS has been conducted in China. The purposes of this study are to analyse: 1)the incidence and outcomes of ARDS in ICU; 2) factors associated the mortality ; and 3) risk factors for development of ARDS .

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2015

Detailed Description

All patients admitted to the participating ICUs during a 6-month period(from January 1, 2015 to July 1,2015 ) will be screened at ICU admission and daily for the occurrence of ARDS ( AECC criteria) for a maximum of 28 days after ICU admission. Data collection: 1. For all patients, Demographic characteristics, admission category, the patient source intervention during ICU , APACHEII , SOFA score and discharge information will be collected 2. For patients with ARDS, data about ABG , parameters of MV, hemodynamic on day0 to day7 and last day of MV will be collected. 3. For patients without ARDS at ICU admission, data about risk factor for ARDS ,such as LIPS score, parameters of MV , and fluid balance on ICU day0 to day7 will be collected.

Arms, Groups and Cohorts

  • ARDS, non-ARDS
    • patients with ARDS and patients without ARDS

Clinical Trial Outcome Measures

Primary Measures

  • incidence of acute respiratory distress syndrome (ARDS)
    • Time Frame: from ICU admission to 28-day of ICU stay
    • incidence of ARDS = the number of patients developing ARDS during ICU / the total number of patients admitted to ICU

Secondary Measures

  • ICU mortality of patients with ARDS
    • Time Frame: followed up to 3 months after inclusion or to ICU discharge, whichever occurred first
  • hospital mortality of patients with ARDS
    • Time Frame: followed up to 3 months after inclusion or to hospital discharge, whichever occurred first

Participating in This Clinical Trial

Inclusion Criteria

all patients age >18 yrs admitted to 24 participating ICUs Exclusion Criteria:

No patients should be excluded (regardless of age, underlying disease, life expectancy, etc).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking Union Medical College Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bin Du, Principal Investigator, MICU of Peking Union Medical College Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.